Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, an HDAC and PI3K Inhibitor, in Subjects With Advanced/Relapsed Solid Tumors

NCT02307240 is registered in ClinicalTrials.gov with Curis, Inc. as lead sponsor.

NCT NCT02307240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02307240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, an HDAC and PI3K Inhibitor, in Subjects With Advanced/Relapsed Solid Tumors
Lead sponsor
Curis, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2014
Completion date
May 31, 2019
Enrollment
43 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade serous ovarian cancer, nut midline carcinoma, solid tumors, triple-negative breast cancer